Lung cancer and immunotherapy: A real-life experience from second line and beyond
Loading...
Files
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Future Medicine Ltd.
Abstract
Aim: This study assessed the efficacy of anti-PD-1/PD-L1 agents in real life when used in second line or beyond. Materials & methods: Patients with advanced non-small-cell lung cancer progressing after standard chemotherapy and receiving immunotherapy in the second line or beyond were included. Results: One hundred and ten patients were included with PD-L1 expression above 50%, between 1-49 and <1% in 38.6, 27.3 and 34.1% of patients, respectively. Checkpoint inhibitors were used as second, third and fourth line in 74.7, 21.8 and 3.5%, respectively. Partial response was observed in 25.6% of patients. Median progression-free survival was 4 months and median overall survival was 8.1 months. Conclusion: Immunotherapies are emerging as important tools in the oncologic field with good responses in real-life practice. © 2019 Future Medicine Ltd.
Description
Keywords
Checkpoint inhibitors, Experience, Immunotherapy, Lung cancer, Non-small-cell lung cancer, Real life, Real-world, Second line, Aged, Antineoplastic agents, immunological, B7-h1 antigen, Biomarkers, tumor, Female, Humans, Lung neoplasms, Male, Middle aged, Prognosis, Retreatment, T-lymphocyte subsets, Treatment outcome, Corticosteroid, Nivolumab, Pembrolizumab, Programmed death 1 ligand 1, Thyroid hormone, Cd274 protein, human, Immunological antineoplastic agent, Tumor marker, Adrenal metastasis, Arthralgia, Article, Bone metastasis, Brain metastasis, Cancer immunotherapy, Cancer staging, Clinical practice, Colitis, Cost effectiveness analysis, Drug cost, Drug efficacy, Fatigue, Human, Hypertransaminasemia, Hypothyroidism, Lebanon, Liver metastasis, Major clinical study, Non small cell lung cancer, Overall survival, Pleura effusion, Pneumonia, Priority journal, Progression free survival, Protein expression, Retrospective study, Thyroiditis, Treatment response, Adverse event, Drug effect, Immunology, Lung tumor, Metabolism, Mortality, Pathology, Procedures, T lymphocyte subpopulation